Keyword Suggestions

Results
 
 
Account Login
 
Username
 
 
 
Password
 
 
 
 
 

Library Navigation

 
 

Browse Conferences

 
 
 
64 Results Found, Showing 1 - 50
Sort By:
View:
Filter By:
Date/Time
Conference
Keyword
My Content
Start Date/Time:
End Date/Time:
 
Go
 
Conference
 
Keywords:
Click here to clear this filter
 
 
Go
Show only the content that I own
 
 
October 17, 2009 - Saturday
 
rating
SA01 - Molecular Characteristics of NSCLC 
Relevancy:
19.22% 
 
Date/Time:
October 17, 2009   8:10am - 8:45am
 
Length:
24m 31s - 36 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
John Minna, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA01 - Molecular Characteristics of NSCLC 
Relevancy:
19.22% 
 
Date/Time:
October 17, 2009   8:10am - 8:45am
 
Length:
24m 31s - 36 Slides  
 
Speaker:
John Minna, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA03 - Molecular Testing in Breast Cancer 
Relevancy:
33.97% 
 
Date/Time:
October 17, 2009   9:20am - 9:55am
 
Length:
32m 29s - 67 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Ronald H. Blum, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA03 - Molecular Testing in Breast Cancer 
Relevancy:
33.97% 
 
Date/Time:
October 17, 2009   9:20am - 9:55am
 
Length:
32m 29s - 67 Slides  
 
Speaker:
Ronald H. Blum, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
46.15% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
46.15% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA10 - How to Enroll Patients in Clinical Trials 
Relevancy:
14.00% 
 
Date/Time:
October 17, 2009   3:00pm - 3:35pm
 
Length:
37m 33s - 34 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Deborah Collyar (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA10 - How to Enroll Patients in Clinical Trials 
Relevancy:
14.00% 
 
Date/Time:
October 17, 2009   3:00pm - 3:35pm
 
Length:
37m 33s - 34 Slides  
 
Speaker:
Deborah Collyar (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 24, 2009 - Thursday
 
rating
A102 - Symptom Interval, Delay in Diagnosis and Access to Care 
Relevancy:
20.37% 
 
Date/Time:
September 24, 2009   1:25pm - 2:05pm
 
Length:
43m 00s - 52 Slides  
 
Total Credits:
0.25 CME/CE  
 
Speaker:
Karen H. Albritton, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
U102 - The Risks and Benefits of Chemoprevention in Prostate Cancer 
Relevancy:
19.21% 
 
Date/Time:
September 24, 2009   1:35pm - 2:05pm
 
Length:
30m 16s - 37 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Andrew J. Stephenson, MD, FRCSC (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM102 - Treatment of Newly Diagnosed Transplant Candidates 
Relevancy:
37.86% 
 
Date/Time:
September 24, 2009   1:35pm - 2:05pm
 
Length:
22m 40s - 32 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Muzzafar H. Qazilbash (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM103 - Treatment of Relapsed and Refractory Myeloma 
Relevancy:
76.31% 
 
Date/Time:
September 24, 2009   2:10pm - 2:40pm
 
Length:
22m 13s - 37 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Sagar Lonial, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON103 - Disclosure 
Relevancy:
100.00% 
 
Date/Time:
September 24, 2009   2:10pm - 2:40pm
 
Length:
33m 39s - 6 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Shirley Johnson, RN, MS, MBA (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM104 - Future Directions in Myeloma 
Relevancy:
49.22% 
 
Date/Time:
September 24, 2009   2:45pm - 3:15pm
 
Length:
40m 52s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Kenneth Anderson (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U105 - How Successful is Radiation Therapy for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer? Can it be Used for Superficial Bladder Cancer? 
Relevancy:
24.29% 
 
Date/Time:
September 24, 2009   3:30pm - 4:00pm
 
Length:
37m 45s - 56 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Howard Sandler, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HN101 - Concomitant Chemoradiotherapy 
Relevancy:
46.51% 
 
Date/Time:
September 24, 2009   3:30pm - 4:00pm
 
Length:
38m 18s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Ezra EW Cohen, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
A107 - Germ Cell Tumors 
Relevancy:
39.38% 
 
Date/Time:
September 24, 2009   3:40pm - 4:00pm
 
Length:
27m 14s - 58 Slides  
 
Total Credits:
0.25 CME/CE  
 
Speaker:
Craig R. Nichols, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
S101 - What is the Optimal Approach to Primary Sarcomas? 
Relevancy:
18.97% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
27m 24s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Robert G. Maki, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HN104 - Induction Chemotherapy 
Relevancy:
28.73% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
14m 09s - 25 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Ezra EW Cohen, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U107 - Surgical Choices for Renal Cell Carcinoma that Optimize Long-Term Renal Function: Open or Laparoscopic? Partial or Complete Nephrectomy? 
Relevancy:
12.35% 
 
Date/Time:
September 24, 2009   4:35pm - 5:05pm
 
Length:
34m 23s - 67 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
William Huang, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM107 - Management of Iron Overload in Hematological Malignancies: Should We Chelate Patients with MDS? 
Relevancy:
29.29% 
 
Date/Time:
September 24, 2009   4:35pm - 5:05pm
 
Length:
20m 06s - 36 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Mikkael A. Sekeres, MD, MS (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HN103 - Update on HPV in Head and Neck Cancer 
Relevancy:
43.73% 
 
Date/Time:
September 24, 2009   4:35pm - 5:05pm
 
Length:
01h 03m 33s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Tanguy Y. Seiwert, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
S103 - Current Best Practices in the Multidisciplinary Management of GIST 
Relevancy:
27.52% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
21m 57s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Robert G. Maki, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U108 - What is the Standard of Care for Metastatic Renal Cell Carcinoma: First-line, Second-line? 
Relevancy:
22.86% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
21m 35s - 56 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Dean F. Bajorin, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM108 - Therapy-Related Myeloid Neoplasms: The Price of Progress? 
Relevancy:
23.82% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
26m 24s - 50 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Wendy Stock, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 25, 2009 - Friday
 
B201 - Neoadjuvant Therapy for Breast Cancer: Lessons Learned and New Directions with Targeted Therapeutics 
Relevancy:
30.17% 
 
Date/Time:
September 25, 2009   8:50am - 9:20am
 
Length:
25m 58s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Laura J. Esserman, MD, MBA (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM201 - Aggressive Lymphoma: Management in 2009 
Relevancy:
15.53% 
 
Date/Time:
September 25, 2009   8:50am - 9:20am
 
Length:
30m 44s - 50 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Jonathan W. Friedberg, MD, MMSC (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON202 - Survivorship Care Plans 
Relevancy:
21.49% 
 
Date/Time:
September 25, 2009   9:25am - 9:55am
 
Length:
30m 24s - 29 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
 
Format:
     
  Synched Audio / Slides
 

 
B203 - Update on Hormone Therapy for Early Stage Breast Cancer: What Treatment, What Duration? 
Relevancy:
54.76% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
28m 33s - 46 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Hope S. Rugo, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM203 - Mantle Cell Lymphoma: How to Select the Best Treatment 
Relevancy:
32.11% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
26m 45s - 54 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Mitchell R. Smith, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON203 - CAM Therapies: The Role of the Nurse in Hypnosis, Guided Imagery and Therapeutic Touch 
Relevancy:
29.38% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
34m 18s - 45 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
 
Format:
     
  Synched Audio / Slides
 

 
B204 - Adjuvant Chemotherapy for Breast Cancer: Are Anthracyclines Out? 
Relevancy:
56.76% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
32m 37s - 28 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Julie R. Gralow, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY204 - Evidence-Based Management of Newly Diagnosed Ovarian Carcinoma 
Relevancy:
34.86% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
34m 08s - 62 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
J. Tate Thigpen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM204 - Challenging Cases in NHL and HL 
Relevancy:
14.64% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
26m 02s - 29 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Ranjana H. Advani, MD (Speaker Disclosure)
 
David G. Maloney, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON204 - GI Cancers: Top Ten Breakthroughs 2008-2009 - A Literature Review 
Relevancy:
32.64% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
27m 57s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Shannon B. Holloway (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B205 - A Primer on Molecular Oncology in Breast Cancer for the Clinician 
Relevancy:
26.15% 
 
Date/Time:
September 25, 2009   2:40pm - 3:10pm
 
Length:
37m 07s - 25 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
John Park, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
B206 - Management of Brain Metastases: New Treatment Modalities 
Relevancy:
12.10% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
33m 45s - 57 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Michelle Melisko, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY206 - A Rational Approach to the Use of Systemic Therapy in Recurrent or Persistent Ovarian Carcinoma 
Relevancy:
18.51% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
36m 03s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Thomas Herzog, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM206 - How I Manage Relapsed NHL - What and When 
Relevancy:
27.56% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
29m 35s - 47 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
David G. Maloney, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B207 - Update on New Treatments for HER2 
Relevancy:
43.64% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
37m 06s - 54 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Hope S. Rugo, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY207 - Debate: Therapy for the Patient with Platinum-Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay 
Relevancy:
25.11% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
25m 13s - 76 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Michael J. Birrer, MD, PhD (Speaker Disclosure)
 
Bradley J. Monk, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 26, 2009 - Saturday
 
rating
L301 - Multi-modality Treatment Strategies in the Treatment of Curative Lung Cancer 
Relevancy:
42.73% 
 
Date/Time:
September 26, 2009   8:15am - 8:45am
 
Length:
25m 45s - 50 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Wayne L. Hofstetter, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM301 - CLL Treatment: Do Pre-treatment Characteristics Guide Current Treatment Choices? 
Relevancy:
41.01% 
 
Date/Time:
September 26, 2009   8:15am - 8:45am
 
Length:
22m 28s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Neil E. Kay, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SC301 - Vitamin D 
Relevancy:
17.35% 
 
Date/Time:
September 26, 2009   8:15am - 8:45am
 
Length:
47m 47s - 36 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Joan M. Lappe, PhD, RN, FAAN (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
L302 - Molecular and Genomic Determinants of Lung Carcinogenesis 
Relevancy:
45.60% 
 
Date/Time:
September 26, 2009   8:50am - 9:20am
 
Length:
29m 09s - 30 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Ignacio I. Wistuba, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
L303 - Current Status of the Neoadjuvant and Adjuvant Chemotherapy of Lung Cancer 
Relevancy:
51.68% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
31m 17s - 48 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Scott Gettinger, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GI303 - Hepatocellular Carcinoma: New Trends and Contemporary Management 
Relevancy:
24.86% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
35m 09s - 59 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Andrew X. Zhu, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM303 - AML Therapy in the "Molecular Genetic" Era: How Does it Impact Therapeutic Approach? 
Relevancy:
41.71% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
40m 03s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Richard Stone, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SC303 - Cutaneous Reactions of Targeted Therapies 
Relevancy:
29.36% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
30m 22s - 33 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Mario E. Lacouture, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
L304 - Current Status of Targeted Therapies in Lung Cancer 
Relevancy:
36.71% 
 
Date/Time:
September 26, 2009   1:30pm - 2:00pm
 
Length:
38m 36s - 54 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Scott Gettinger, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
64 Results Found, Showing 1 - 50
Previous Page |   Go To Page:   | Next Page